Key terms
About COGT
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest COGT news
Feb 27
11:40pm ET
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Celldex (CLDX) and Laboratory (LH)
Feb 27
7:30am ET
Analysts Offer Insights on Healthcare Companies: Cigna (CI), Cogent Biosciences (COGT) and Canopy Growth (CGC)
Feb 26
9:40am ET
Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)
Feb 26
9:24am ET
Cogent Biosciences price target raised to $19 from $13 at H.C. Wainwright
Feb 26
8:03am ET
Cogent Biosciences expects cash to fund requirements into 2027
Feb 26
8:02am ET
Cogent Biosciences reports Q4 EPS (63c), consensus (55c)
Feb 26
6:37am ET
Cogent Biosciences price target raised to $13 from $11 at Citi
Feb 26
4:58am ET
Cogent Biosciences downgraded to Neutral from Outperform at Baird
Feb 26
4:40am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)
Feb 23
8:40am ET
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX)
Feb 23
8:31am ET
Cogent Biosciences price target raised to $18 from $15 at Needham
Feb 23
7:11am ET
Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Cogent Biosciences (COGT)
Feb 23
6:06am ET
Buy Rating Affirmed for Cogent Biosciences as Bezuclastinib Showcases Strong Market Potential
Feb 22
2:32pm ET
Cogent Biosciences announces ‘positive’ Part 1b data from SUMMIT trial
Feb 22
12:17am ET
Buy Rating Affirmed on Cogent Biosciences Amid Positive Outlook for Bezuclastinib’s Efficacy and Safety
Feb 15
1:17am ET
Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potential
Feb 14
6:52pm ET
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Cogent Biosciences (COGT)
Feb 14
7:21am ET
Cogent Biosciences announces oversubscribed $225M private placement
Feb 14
7:20am ET
Cogent Biosciences sells 17M shares at $7.50 in private placement
Feb 12
5:25am ET
Cogent Biosciences: A Balanced Buy Rating Ahead of Key Data Release
Feb 08
5:07am ET
Buy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospects
Feb 08
4:54am ET
Cogent Biosciences initiated with a Buy at Citi
Jan 09
8:08am ET
Cogent Biosciences announces planned 2024 milestones
Dec 15
6:28am ET
Buy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trial
Dec 15
6:17am ET
Cogent Biosciences price target lowered to $13 from $27 at H.C. Wainwright
Dec 15
6:17am ET
Cogent Biosciences price target lowered by $14 at H.C. Wainwright, here’s why
Dec 13
1:17am ET
Maintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinib
Dec 11
12:56pm ET
Wedbush downgrades Cogent Biosciences to Neutral, cuts price target to $5
Dec 11
12:52pm ET
Cogent Biosciences just downgraded at Wedbush, here’s why
Dec 11
10:45am ET
Needham biotechnology analyst to hold an analyst/industry conference call
Dec 11
9:41am ET
Cogent Biosciences trading resumes
No recent news articles are available for COGT
No recent press releases are available for COGT
COGT Financials
Key terms
Ad Feedback
COGT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
COGT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range